Patient Safety and the Viagra Connect Assessment

Prevalence, comorbidities, and risk factors of erectile dysfunction: results from a prospective real-world study in the United Kingdom.

• The drug improves quality of life for many men with ED.
• It is part of a broader treatment approach, including counseling.
• Mental health can impact erectile function.
• Lifestyle changes can enhance medication effectiveness.
• Support groups may provide additional help.
• Consult your doctor if ED persists despite treatment.

Burri A, Porst H. Results from an online survey investigating ED patients’ insights and treatment expectations. EAU guidelines on sexual and reproductive health.

• Viagra Connect may interact with certain medications.
• Be aware of potential contraindications.
• Not for use with certain blood pressure medicines.
• Consult a healthcare professional before starting.
• Do not use if you have recent heart surgery.
• Regular check-ups can ensure safe use of ED medication.

Padma-Nathan H. Sildenafil citrate (Viagra) treatment for erectile dysfunction: an updated profile of response and effectiveness. Medicines & Healthcare Products Regulatory Agency M. Public assessment report – prescription only medicine to pharmacy medicine reclassification: Viagra Connect® 50mg film-coated tablets, Sildenafil Citrate (PL 00165/0392 – 0001, 2017). A web-based survey of UK pharmacists to assess the effectiveness of Viagra Connect® additional risk minimisation measures. A Web-Based Survey of Patients Dispensed Viagra Connect Behind the Counter in the viagra black UK: An Evaluation of the Effectiveness of Additional Risk Minimization Measures.

What is Eroxon Gel

Prevalence, comorbidities, and risk factors of erectile dysfunction: results from a prospective real-world study in the United Kingdom. Burri A, Porst H. Results from an online survey investigating ED patients’ insights and treatment expectations. EAU guidelines on sexual and reproductive health. Padma-Nathan H.

Viagra: Different Dosages

Sildenafil citrate (Viagra) treatment for erectile dysfunction: an updated profile of response and effectiveness. Medicines & Healthcare Products Regulatory Agency M. Public assessment report – prescription only medicine to pharmacy medicine reclassification: Viagra Connect® 50mg film-coated tablets, Sildenafil Citrate (PL 00165/0392 – 0001, 2017). A web-based survey of UK pharmacists to assess the effectiveness of Viagra Connect® additional risk minimisation measures. A Web-Based Survey of Patients Dispensed Viagra Connect Behind the Counter in the viagra black UK: An Evaluation of the Effectiveness of Additional Risk Minimization Measures.

How long does it take for Viagra Connect to work?

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, 3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, 3.0) License.

By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

Recommended dose

In another web-based survey conducted between March 2018 and April 2019, men aged ≥18 years with self-reported ED who were dispensed VC reported having higher number of physician/nurse practitioner and pharmacist visits during the one-year period after their first VC dispension, comparing to those who were not dispensed VC.Citation14,Citation17 Most of the surveyed patients reported that, during their first purchase of VC, they had been advised by the pharmacist regarding how to take VC correctly (85.5%), of VC’s possible side effects which requires the patients to discontinue VC and consult their doctors (82.2%).

Tadalafil (Cialis)

For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

• Education on safe use is essential for users.
• Proper storage ensures medication potency.
• Keep out of reach of children.
• Be aware of possible drug interactions.
• Medication should be used only under guidance.
• Regular consultation can prevent complications.

A new quick reference guide to the supply of Viagra Connect (sildenafil) as a pharmacy (P) medicine has been released by the Royal Pharmaceutical Society (RPS). In November 2017, 50mg tablets of Viagra Connect were reclassified from a prescription-only medicine to P status. The tablets went on sale as a P medicine on 27 March 2018. The guide explains what pharmacists and pharmacy staff need to consider before supplying Viagra as a P medicine, and provides advice on how to undertake the patient consulation. The guidance also outlines the public health benefits of the medicine’s reclassification: namely, the opportunity for early identification of cardiovascular risk.

The full ‘Sildenafil 50mg film-coated tablets, P medicine quick reference guide’ can be downloaded from the RPS website. A national additional risk minimization measures (aRMMs) program was implemented to train pharmacists for safe supply of non-prescription Viagra Connect® (VC) to erectile dysfunction (ED) patients in United Kingdom (UK). A survey aimed to evaluate the effectiveness of aRMMs.

A cross-sectional, web-based survey enrolled ED patients who purchased at least 1 supply of VC in UK, using a structured self-administered questionnaire. The final sample had 297 patients, who reported that pharmacists inquired about blood pressure and heart comorbidities (91.9%), relevant illnesses (87.9%), medications (86.5%), ED diagnosis (82.2%), and were advised to consult their doctor regarding ED (51.2%). A majority (68.7%) also indicated that they had received advice on lifestyle modifications to manage their ED-related health risks. This survey provided a reasonable confirmation of the effectiveness of the VC aRMMs program and assurance that ED patients, when requesting and purchasing VC in UK pharmacies, are assessed appropriately for suitability of VC and receive the appropriate advice from pharmacists. A national india viagra additional risk minimization measures (aRMMs) program was implemented to train pharmacists for safe supply of non-prescription VC to erectile dysfunction (ED) patients in United Kingdom (UK). The final sample had 297 patients, who reported that pharmacists inquired about blood pressure and heart comorbidities, relevant illnesses, medications, ED diagnosis, and were advised to consult their doctor regarding ED. A majority also indicated that they had received advice on lifestyle modifications to manage their ED-related health risks. Erectile dysfunction (ED) is the inability to achieve or maintain an erection that is sufficient for satisfactory sexual performance.Citation1 The overall prevalence of self-reported ED in men across aged 40–70 years has been estimated to be 45.2%.Citation2 Organic (ie, neurogenic, endocrinological, vasculogenic, or drug-induced), psychogenic, or mixed causes may attribute to ED.Citation3,Citation4 ED may be a presenting symptom of undetected or underlying cardiovascular disease (CVD) in men.Citation5 ED and CVD share several risk factors including advanced age, tobacco use, excessive alcohol consumption, diabetes mellitus, hyperlipidemia, obesity, depression among others.Citation6,Citation7 Additionally, ED is also known to cause substantial negative effects on the patient’s self-esteem, quality of life and emotional status.Citation8,Citation9 There are several treatment options recommended by European guidelines for ED management including intracavernosal injection, vacuum device, oral therapy with phosphodiesterase type 5 (PDE-5) inhibitors, topical/intra-urethral alprostadil along with lifestyle modification and patient education. Amongst all the treatment options, pharmacological treatment with oral PDE-5 inhibitors remain the main stay of treatment of ED.Citation10 Sildenafil citrate is a potent and selective inhibitor of cyclic- guanosine monophosphate-specific phosphodiesterase enzyme which causes relaxation of smooth muscle in the corpus cavernosum.Citation11 Eventually, sildenafil restores the natural erectile response to sexual stimulation and has been effectively used in the treatment of patient population with ED of varying etiologies and with diverse comorbidities.Citation3,Citation4,Citation12 Sildenafil citrate (Viagra®), supplied via prescription, was approved in the European Union (EU) in 1998 for treatment of ED.

A Decentralized Procedure (DCP) application for non-prescription (ie, behind the counter) 50 mg sildenafil (marketed as Viagra Connect® [VC] 50 mg film-coated tablets) was approved in the UK in November 2017 and became available in pharmacies in the UK in April 2018.Citation13 This launch of VC in the UK, and its availability as a “behind the counter” (pharmacist-supervised) medicine augments the availability of pharmacists to help men to deal with both the physical and emotional impact of ED, and other wider potential health concerns associated with ED. The findings and recommendations from the survey pre-testing were incorporated into the final version and tested in two pilot surveys for further refinement.Citation8,Citation14 This patient survey was administered online anonymously and expected to take approximately 5 minutes to complete by the participants. The survey included questions/statements that inquired about the patient’s experience at the point of VC supply in the pharmacy, including whether they were: Assessed for viagra tablet for sex suitability for VC (eg, for cardiovascular and other health conditions), Assessed for suitability for VC (eg, for cardiovascular and other health conditions), Advised by a pharmacist to consult their doctor within 6 months of first supply, Advised by a pharmacist to consult their doctor within 6 months of first supply, Visited their doctor or planned to visit their doctor very soon, Visited their doctor or planned to visit their doctor very soon, Advised by their pharmacist about the safe use of VC, and Advised by their pharmacist about the safe use of VC, and Advised by their pharmacist about potential causes of ED and offered lifestyle advice. Advised by their pharmacist about potential causes of ED and offered lifestyle advice. Further details on patient demographics, pharmacy and patient characteristics are shown (). The participants’ experience of whether they were assessed for suitability for VC use by their pharmacist the first time they asked for VC is shown (). Patient’s experience of whether they were advised by the pharmacist to consult their doctor during their first request for VC is shown (). Patients’ experience with visiting or planning to visit their doctor in the near future are shown (). 80.1% (n = 238) reported that their pharmacist informed them that ED can be caused by underlying conditions such as high BP, diabetes, high cholesterol, and heart disease, while 68.7% (n = 204) reported that they had received lifestyle advice from the pharmacist (). In general, if the participants reported having ED, the pharmacists were more likely to assess their suitability for VC and provide advice on appropriate use of VC and on their need to see doctors ().

Hycosan Extra Dry Eye Drops - 7.5ml - Pack of 3

A new quick reference guide to the supply of Viagra Connect (sildenafil) as a pharmacy (P) medicine has been released by the Royal Pharmaceutical Society (RPS). In November 2017, 50mg tablets of Viagra Connect were reclassified from a prescription-only medicine to P status. The tablets went on sale as a P medicine on 27 March 2018. The guide explains what pharmacists and pharmacy staff need to consider before supplying Viagra as a P medicine, and provides advice on how to undertake the patient consulation. The guidance also outlines the public health benefits of the medicine’s reclassification: namely, the opportunity for early identification of cardiovascular risk.

What is the difference between Prescription Viagra and Viagra Connect?

The full ‘Sildenafil 50mg film-coated tablets, P medicine quick reference guide’ can be downloaded from the RPS website. A national additional risk minimization measures (aRMMs) program was implemented to train pharmacists for safe supply of non-prescription Viagra Connect® (VC) to erectile dysfunction (ED) patients in United Kingdom (UK). A survey aimed to evaluate the effectiveness of aRMMs. A cross-sectional, web-based survey enrolled ED patients who purchased at least 1 supply of VC in UK, using a structured self-administered questionnaire. The final sample had 297 patients, who reported that pharmacists inquired about blood pressure and heart comorbidities (91.9%), relevant illnesses (87.9%), medications (86.5%), ED diagnosis (82.2%), and were advised to consult their doctor regarding ED (51.2%).

Ethics approval

A majority (68.7%) also indicated that they had received advice on lifestyle modifications to manage their ED-related health risks. This survey provided a reasonable confirmation of the effectiveness of the VC aRMMs program and assurance that ED patients, when requesting and purchasing VC in UK pharmacies, are assessed appropriately for suitability of VC and receive the appropriate advice from pharmacists. A national india viagra additional risk minimization measures (aRMMs) program was implemented to train pharmacists for safe supply of non-prescription VC to erectile dysfunction (ED) patients in United Kingdom (UK). The final sample had 297 patients, who reported that pharmacists inquired about blood pressure and heart comorbidities, relevant illnesses, medications, ED diagnosis, and were advised to consult their doctor regarding ED. A majority also indicated that they had received advice on lifestyle modifications to manage their ED-related health risks. One of the key strengths of the present study is that it has the benefits of implications from two previously conducted pilot surveys.Citation8,Citation14 The first used a consumer panel and identified significant selection and response biases such that there was a high likelihood that the results would not be representative of the patient population seeking to purchase VC.

Additional information

Erectile dysfunction (ED) is the inability to achieve or maintain an erection that is sufficient for satisfactory sexual performance.Citation1 The overall prevalence of self-reported ED in men across aged 40–70 years has been estimated to be 45.2%.Citation2 Organic (ie, neurogenic, endocrinological, vasculogenic, or drug-induced), psychogenic, or mixed causes may attribute to ED.Citation3,Citation4 ED may be a presenting symptom of undetected or underlying cardiovascular disease (CVD) in men.Citation5 ED and CVD share several risk factors including advanced age, tobacco use, excessive alcohol consumption, diabetes mellitus, hyperlipidemia, obesity, depression among others.Citation6,Citation7 Additionally, ED is also known to cause substantial negative effects on the patient’s self-esteem, quality of life and emotional status.Citation8,Citation9 There are several treatment options recommended by European guidelines for ED management including intracavernosal injection, vacuum device, oral therapy with phosphodiesterase type 5 (PDE-5) inhibitors, topical/intra-urethral alprostadil along with lifestyle modification and patient education. Amongst all the treatment options, pharmacological treatment with oral PDE-5 inhibitors remain the main stay of treatment of ED.Citation10 Sildenafil citrate is a potent and selective inhibitor of cyclic- guanosine monophosphate-specific phosphodiesterase enzyme which causes relaxation of smooth muscle in the corpus cavernosum.Citation11 Eventually, sildenafil restores the natural erectile response to sexual stimulation and has been effectively used in the treatment of patient population with ED of varying etiologies and with diverse comorbidities.Citation3,Citation4,Citation12 Sildenafil citrate (Viagra®), supplied via prescription, was approved in the European Union (EU) in 1998 for treatment of ED. A Decentralized Procedure (DCP) application for non-prescription (ie, behind the counter) 50 mg sildenafil (marketed as Viagra Connect® [VC] 50 mg film-coated tablets) was approved in the UK in November 2017 and became available in pharmacies in the UK in April 2018.Citation13 This launch of VC in the UK, and its availability as a “behind the counter” (pharmacist-supervised) medicine augments the availability of pharmacists to help men to deal with both the physical and emotional impact of ED, and other wider potential health concerns associated with ED. The findings and recommendations from the survey pre-testing were incorporated into the final version and tested in two pilot surveys for further refinement.Citation8,Citation14 This patient survey was administered online anonymously and expected to take approximately 5 minutes to complete by the participants. The survey included questions/statements that inquired about the patient’s experience at the point of VC supply in the pharmacy, including whether they were: Assessed for viagra tablet for sex suitability for VC (eg, for cardiovascular and other health conditions), Assessed for suitability for VC (eg, for cardiovascular and other health conditions), Advised by a pharmacist to consult their doctor within 6 months of first supply, Advised by a pharmacist to consult their doctor within 6 months of first supply, Visited their doctor or planned to visit their doctor very soon, Visited their doctor or planned to visit their doctor very soon, Advised by their pharmacist about the safe use of VC, and Advised by their pharmacist about the safe use of VC, and Advised by their pharmacist about potential causes of ED and offered lifestyle advice.

Study Variables

Advised by their pharmacist about potential causes of ED and offered lifestyle advice. Further details on patient demographics, pharmacy and patient characteristics are shown (). The participants’ experience of whether they were assessed for suitability for VC use by their pharmacist the first time they asked for VC is shown (). Patient’s experience of whether they were advised by the pharmacist to consult their doctor during their first request for VC is shown (). Patients’ experience with visiting or planning to visit their doctor in the near future are shown ().

Viagra Connect Sildenafil 50mg Tablets 8s

80.1% (n = 238) reported that their pharmacist informed them that ED can be caused by underlying conditions such as high BP, diabetes, high cholesterol, and heart disease, while 68.7% (n = 204) reported that they had received lifestyle advice from the pharmacist (). In general, if the participants reported having ED, the pharmacists were more likely to assess their suitability for VC and provide advice on appropriate use of VC and on their need to see doctors (). One of the key strengths of the present study is that it has the benefits of implications from two previously conducted pilot surveys.Citation8,Citation14 The first used a consumer panel and identified significant selection and response biases such that there was a high likelihood that the results would not be representative of the patient population seeking to purchase VC. The pharmacist survey has been published allowing us to compare the findings between the patient survey and pharmacist survey.Citation14–16 Regarding pharmacists’ assessment of patients’ suitability for VC at the time the patients purchased VC in pharmacies, most patients in the patient survey reported they had been asked about their BP and heart conditions (91.9%), any other illnesses (87.9%) or concomitant medications use (86.5%). The results of this patient survey support the fact that the pharmacists’ knowledge is being put into practice when a patient presents for the first time to purchase VC.Citation14–17 In this patient survey, 51.2% of the patients reported that they were advised, at their first-time purchase of VC, to see their doctor within 6 months or shorter. The pharmacist survey has been published allowing us to compare the findings between the patient survey and pharmacist survey.Citation14–16 Regarding pharmacists’ assessment of patients’ suitability for VC at the time the patients purchased VC in pharmacies, most patients in the patient survey reported they had been asked about their BP and heart conditions (91.9%), any other illnesses (87.9%) or concomitant medications use (86.5%). The results of this patient survey support the fact that the pharmacists’ knowledge is being put into practice when a patient presents for the first time to purchase VC.Citation14–17 In this patient survey, 51.2% of the patients reported that they were advised, at their first-time purchase of VC, to see their doctor within 6 months or shorter. In another web-based survey conducted between March 2018 and April 2019, men aged ≥18 years with self-reported ED who were dispensed VC reported having higher number of physician/nurse practitioner and pharmacist visits during the one-year period after their first VC dispension, comparing to those who were not dispensed VC.Citation14,Citation17 Most of the surveyed patients reported that, during their first purchase of VC, they had been advised by the pharmacist regarding how to take VC correctly (85.5%), of VC’s possible side effects which requires the patients to discontinue VC and consult their doctors (82.2%).